Prostamax is a synthetic Khavinson peptide marketed for prostate and urogenital support with limited preliminary research, and users most commonly take it for prostate health support, which appears in 14 community reports with about 79 % positive feedback. Most users report taking around 1 mg daily (with a reported range of 0.5–5 mg), while some clinicians prescribe 20 mg subcutaneously per day, and timing and cycling are not standardized in either community or clinician reports. It carries no FDA‑approved indication, so all human use is off‑label or compounded.
Data last updated
Measured on 4 of 6 axes
Evidence shape
The evidence for Prostamax is currently classified as animal‑only, reflecting exclusively preclinical/mechanistic research and lacking any published human studies. The breadth shows a single indication mapped from animal data, the depth records zero registered trials, and the quality reports no completed trials. Consequently, the only signal available at this stage is from preclinical work, with an absence of human trials meaning there is no clinical evidence to assess safety or efficacy.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 2 out-of-stock offers not shown
Some links are affiliate links. This never affects our rankings or inclusion.
How Prostamax is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
Clinician practice uses a single subcutaneous dose of 20 mg, with no documented frequency or cycling protocol; the source reports only this amount.
Most community users administer about 1 mg of Prostamax subcutaneously once daily (dose range 0.5–5 mg); a smaller subset takes 5 mg twice daily, and several respondents did not state a specific schedule.